ContraFect Corp
NASDAQ:CFRX
Intrinsic Value
ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for... [ Read More ]
The intrinsic value of one CFRX stock under the Base Case scenario is 2.6909 USD. Compared to the current market price of 0.0271 USD, ContraFect Corp is Undervalued by 99%.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of ContraFect Corp's business.
What risks and challenges
does ContraFect Corp face in the near future?
Summarize the latest earnings report
of ContraFect Corp.
Provide P/E
for ContraFect Corp and its competitors.
Balance Sheet Decomposition
ContraFect Corp
Current Assets | 16.5m |
Cash & Short-Term Investments | 14.4m |
Receivables | 600k |
Other Current Assets | 1.5m |
Non-Current Assets | 2.7m |
PP&E | 2.6m |
Other Non-Current Assets | 110k |
Current Liabilities | 16.5m |
Accounts Payable | 11.6m |
Accrued Liabilities | 4.9m |
Other Current Liabilities | -10k |
Non-Current Liabilities | 3.9m |
Other Non-Current Liabilities | 3.9m |
Earnings Waterfall
ContraFect Corp
Revenue
|
0
USD
|
Operating Expenses
|
-39.3m
USD
|
Operating Income
|
-39.3m
USD
|
Other Expenses
|
3.5m
USD
|
Net Income
|
-35.9m
USD
|
Free Cash Flow Analysis
ContraFect Corp
What is Free Cash Flow?
CFRX Profitability Score
Profitability Due Diligence
ContraFect Corp's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Score
ContraFect Corp's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
CFRX Solvency Score
Solvency Due Diligence
ContraFect Corp's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
ContraFect Corp's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CFRX Price Targets Summary
ContraFect Corp
Ownership
CFRX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CFRX Price
ContraFect Corp
Average Annual Return | -26.48% |
Standard Deviation of Annual Returns | 60.06% |
Max Drawdown | -100% |
Market Capitalization | 145.2k USD |
Shares Outstanding | 5 358 800 |
Percentage of Shares Shorted | 2.75% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. The company is headquartered in Yonkers, New York and currently employs 38 full-time employees. The company went IPO on 2014-07-29. The firm is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase (CF-301), is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa and has demonstrated potent in vivo activity against extensively drug-resistant (XDR) strains. The company has developed an, engineered variant of exebacase, known as CF-296. The company is conducting further in vitro and in vivo characterization of CF-296 to evaluate the full profile of this compound.